137 related articles for article (PubMed ID: 8740144)
1. Inhibition of T cell cAMP formation by cyclosporin A and FK506.
Ockenfels HM; Wagner SN; Oeljeklaus P; Schneck B; Nussbaum G; Jakobs KH; Goos M
Naunyn Schmiedebergs Arch Pharmacol; 1996 Apr; 353(5):513-6. PubMed ID: 8740144
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of cyclic AMP response element-binding protein/cyclic AMP response element-mediated transcription by the immunosuppressive drugs cyclosporin A and FK506 depends on the promoter context.
Siemann G; Blume R; Grapentin D; Oetjen E; Schwaninger M; Knepel W
Mol Pharmacol; 1999 Jun; 55(6):1094-100. PubMed ID: 10347253
[TBL] [Abstract][Full Text] [Related]
3. Rapamycin antagonizes cyclosporin A- and tacrolimus (FK506)-mediated augmentation of linker for activation of T cell expression in T cells.
Cho CS; Chang Z; Elkahwaji J; Scheunemann TL; Manthei ER; Colburn M; Knechtle SJ; Hamawy MM
Int Immunol; 2003 Nov; 15(11):1369-78. PubMed ID: 14565935
[TBL] [Abstract][Full Text] [Related]
4. The immunosuppressive drugs cyclosporin A and FK506 inhibit calcineurin phosphatase activity and gene transcription mediated through the cAMP-responsive element in a nonimmune cell line.
Schwaninger M; Blume R; Oetjen E; Knepel W
Naunyn Schmiedebergs Arch Pharmacol; 1993 Nov; 348(5):541-5. PubMed ID: 7509460
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of CREB- and cAMP response element-mediated gene transcription by the immunosuppressive drugs cyclosporin A and FK506 in T cells.
Krüger M; Schwaninger M; Blume R; Oetjen E; Knepel W
Naunyn Schmiedebergs Arch Pharmacol; 1997 Oct; 356(4):433-40. PubMed ID: 9349628
[TBL] [Abstract][Full Text] [Related]
6. Human T cell responses to human and porcine endothelial cells are highly sensitive to cyclosporin A and FK506 in vitro.
Batten P; McCormack AM; Page CS; Yacoub MH; Rose ML
Transplantation; 1999 Nov; 68(10):1552-60. PubMed ID: 10589954
[TBL] [Abstract][Full Text] [Related]
7. Activation-induced cell death in murine T cell hybridomas. Differential regulation of Fas (CD95) versus Fas ligand expression by cyclosporin A and FK506.
Brunner T; Yoo NJ; LaFace D; Ware CF; Green DR
Int Immunol; 1996 Jul; 8(7):1017-26. PubMed ID: 8757947
[TBL] [Abstract][Full Text] [Related]
8. The hydroxylamine of sulfamethoxazole synergizes with FK506 and cyclosporin A, inhibiting T-cell proliferation.
Hess DA; Bird IA; Almawi WY; Rieder MJ
J Pharmacol Exp Ther; 1997 Apr; 281(1):540-8. PubMed ID: 9103542
[TBL] [Abstract][Full Text] [Related]
9. Different effects of cyclosporine a and FK506 on potassium transport systems in MDCK cells.
Aker S; Heering P; Kinne-Saffran E; Deppe C; Grabensee B; Kinne RK
Exp Nephrol; 2001; 9(5):332-40. PubMed ID: 11549851
[TBL] [Abstract][Full Text] [Related]
10. The effect of cyclosporin A and FK 506 on the cAMP content in psoriatic keratinocytes.
Ockenfels HM; Nussbaum G; Schneck B; Wagner SN; Haen E; Goos M
Skin Pharmacol; 1996; 9(4):281-8. PubMed ID: 8896120
[TBL] [Abstract][Full Text] [Related]
11. Superior T-cell suppression by rapamycin and FK506 over rapamycin and cyclosporine A because of abrogated cytotoxic T-lymphocyte induction, impaired memory responses, and persistent apoptosis.
Koenen HJ; Michielsen EC; Verstappen J; Fasse E; Joosten I
Transplantation; 2003 May; 75(9):1581-90. PubMed ID: 12792519
[TBL] [Abstract][Full Text] [Related]
12. Effect of cyclosporin and tacrolimus (FK506) on the antigen-induced mediator release, membrane potential and 86Rb+/K+ and Ca2+ fluxes in the RBL-2H3 cell line.
Narenjkar J; Assem el-SK; Wan BY; Marsh S; Ezeamuzie CI
Int Immunopharmacol; 2006 May; 6(5):742-9. PubMed ID: 16546704
[TBL] [Abstract][Full Text] [Related]
13. Cyclosporin a and tacrolimus (FK506) differentially alter T-cell receptor expression in vivo.
Miller JL; Ericson SG
Immunopharmacol Immunotoxicol; 2007; 29(1):105-18. PubMed ID: 17464771
[TBL] [Abstract][Full Text] [Related]
14. Molecular and biological actions of cyclosporin A and FK506 on T cell development and function.
Holländer GA; Bierer BE; Burakoff SJ
Transfus Sci; 1994 Sep; 15(3):207-20. PubMed ID: 10155542
[TBL] [Abstract][Full Text] [Related]
15. Cyclosporin A, but not FK506, increases arachidonic acid release and inhibits proliferation of pituitary corticotrope tumor cells.
Pompeo A; Baldassare M; Luini A; Buccione R
Life Sci; 1999; 64(10):837-46. PubMed ID: 10096434
[TBL] [Abstract][Full Text] [Related]
16. Cyclosporin a inhibits calcineurin/nuclear factor of activated T-cells signaling and induces apoptosis in retinoblastoma cells.
Eckstein LA; Van Quill KR; Bui SK; Uusitalo MS; O'Brien JM
Invest Ophthalmol Vis Sci; 2005 Mar; 46(3):782-90. PubMed ID: 15728531
[TBL] [Abstract][Full Text] [Related]
17. Neither cyclosporin A nor FK506 affects adenylate cyclase responses of fetal rat keratinizing epidermal cells (FRSK cells) at concentrations that inhibit thymidine incorporation.
Takahashi H; Iizuka H
J Dermatol Sci; 1993 Dec; 6(3):235-9. PubMed ID: 7511000
[TBL] [Abstract][Full Text] [Related]
18. Hair growth-stimulating effects of cyclosporin A and FK506, potent immunosuppressants.
Yamamoto S; Kato R
J Dermatol Sci; 1994 Jul; 7 Suppl():S47-54. PubMed ID: 7528050
[TBL] [Abstract][Full Text] [Related]
19. The effect of the new immunosuppressive drug FK506 on the formation of secondary metabolites of cyclosporin A.
Bauer S; Brockmöller J; Kewitz H; Roots I
Int J Clin Pharmacol Ther Toxicol; 1992 Nov; 30(11):540-2. PubMed ID: 1283385
[TBL] [Abstract][Full Text] [Related]
20. Cyclosporin and tacrolimus increase plasma levels of adenosine in kidney transplanted patients.
Capecchi PL; Rechichi S; Lazzerini PE; Collini A; Guideri F; Ruggieri G; Carmellini M; Laghi-Pasini F
Transpl Int; 2005 Mar; 18(3):289-95. PubMed ID: 15730488
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
